Literature DB >> 21170730

Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.

Peter M H Heegaard1, Laurence Dedieu, Nicholas Johnson, Marie-Frédérique Le Potier, Michael Mockey, Franco Mutinelli, Thomas Vahlenkamp, Marta Vascellari, Nanna Skall Sørensen.   

Abstract

Modern adjuvants should induce strong and balanced immune responses, and it is often desirable to induce specific types of immunity. As an example, efficient Th1-immunity-inducing adjuvants are highly in demand. Such adjuvants promote good cell-mediated immunity against subunit vaccines that have low immunogenicity themselves. The development of such adjuvants may take advantage of the increased knowledge of the molecular mechanisms and factors controlling these responses. However, knowledge of such molecular details of immune mechanisms is relatively scarce for species other than humans and laboratory rodents, and in addition, there are special considerations pertaining to the use of adjuvants in veterinary animals, such as production and companion animals. With a focus on veterinary animals, this review highlights a number of approaches being pursued, including cytokines, CpG oligonucleotides, microparticles and liposomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170730     DOI: 10.1007/s00705-010-0863-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  31 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines.

Authors:  Shishir Kumar Gupta; Preety Bajwa; Rajib Deb; Madhan Mohan Chellappa; Sohini Dey
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

3.  Duration of immunity after rabies vaccination in dogs: The Rabies Challenge Fund research study.

Authors:  W Jean Dodds; Laurie J Larson; Kris L Christine; Ronald D Schultz
Journal:  Can J Vet Res       Date:  2020-04       Impact factor: 1.310

4.  Immunostimulatory effects of recombinant Erysipelothrix rhusiopathiae expressing porcine interleukin-18 in mice and pigs.

Authors:  Yohsuke Ogawa; Yu Minagawa; Fang Shi; Masahiro Eguchi; Yoshihiro Muneta; Yoshihiro Shimoji
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

5.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

6.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

7.  DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies.

Authors:  Jordi M Argilaguet; Eva Pérez-Martín; Miquel Nofrarías; Carmina Gallardo; Francesc Accensi; Anna Lacasta; Mercedes Mora; Maria Ballester; Ivan Galindo-Cardiel; Sergio López-Soria; José M Escribano; Pedro A Reche; Fernando Rodríguez
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

8.  Evaluation of Montanide™ ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis.

Authors:  Seung I Jang; Duk Kyung Kim; Hyun S Lillehoj; Sung Hyen Lee; Kyung Woo Lee; François Bertrand; Laurent Dupuis; Sébastien Deville; Juliette Ben Arous; Erik P Lillehoj
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

9.  Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.

Authors:  Shu-Chun Chuang; Jing-Chun Ko; Chaio-Ping Chen; Jia-Tze Du; Chung-Da Yang
Journal:  Parasit Vectors       Date:  2013-02-11       Impact factor: 3.876

10.  MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens.

Authors:  Matthias Liniger; Artur Summerfield; Nicolas Ruggli
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.